1745-6215-15-371.pdf (1.3 MB)
Download file

The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial

Download (1.3 MB)
journal contribution
posted on 22.06.2015, 08:23 by Sheraz A. Nazir, J. N. Khan, I. Z. Mahmoud, J. P. Greenwood, D. J. Blackman, V. Kunadian, M. Been, K. R. Abrams, R. Wilcox, A. A. Adgey, G. P. McCann, A. H. Gershlick
Microvascular obstruction (MVO) secondary to ischaemic-reperfusion injury is an important but underappreciated determinant of short- and longer-term outcome following percutaneous coronary intervention (PCI) treatment of ST-elevation myocardial infarction (STEMI). Several small studies have demonstrated a reduction in the degree of MVO utilising a variety of vasoactive agents, with adenosine and sodium nitroprusside (SNP) being most evaluated. However, the evidence base remains weak as the trials have had variable endpoints, differing drug doses and delivery. As such, the results regarding benefit are conflicting.

History

Citation

Trials, 2014, 15, p. 371

Author affiliation

/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Cardiovascular Sciences

Version

VoR (Version of Record)

Published in

Trials

Publisher

BioMed Central

eissn

1745-6215

Copyright date

2014

Available date

22/06/2015

Publisher version

http://www.trialsjournal.com/content/15/1/371

Notes

PMCID: PMC4189551

Language

en